Olanzapine
- Generic Name
- Olanzapine
- Brand Names
- Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20N4S
- CAS Number
- 132539-06-1
- Unique Ingredient Identifier
- N7U69T4SZR
- Background
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...
- Indication
Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...
- Associated Conditions
- Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Characterizing Response to Antipsychotics in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- The Royal Ottawa Mental Health Centre
- Target Recruit Count
- 40
- Registration Number
- NCT06159322
- Locations
- 🇨🇦
The Royal's Institute of Mental Health Research, Ottawa, Ontario, Canada
Psychopharmacological Treatment of Emotional Distress
- Conditions
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 80
- Registration Number
- NCT06133114
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
The Danish Out-of-Hospital Cardiac Arrest Study
- Conditions
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Christian Hassager
- Target Recruit Count
- 1000
- Registration Number
- NCT05895838
- Locations
- 🇩🇰
The Department of Intensive Care, Aalborg University Hospital, Aalborg, Aalborg, Denmark
🇩🇰Dept. of Cardiology, The Heart Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Capital Region Of Denmark, Denmark
🇩🇰The Department of Intensive Care, Aarhus University Hospital, Aarhus, Aarhus, Denmark
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-08-14
- Target Recruit Count
- 520
- Registration Number
- NCT05814640
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Province, China
A Study of Olanzapine in Patients With Acute Agitation
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 318
- Registration Number
- NCT05803642
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Solid or or Metastatic Esophagogastric, Hepatopancreaticobiliary, or Lung Cancer
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 66
- Registration Number
- NCT05705492
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge from Ambulatory Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Yale University
- Target Recruit Count
- 455
- Registration Number
- NCT05676294
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients
- Conditions
- Interventions
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 40
- Registration Number
- NCT05669742
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT05403580
Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-07-28
- Target Recruit Count
- 210
- Registration Number
- NCT05346731
- Locations
- 🇷🇺
Zhukov Nikolay, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.